06.06 07:00 | *DJ Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update |
06.06 07:00 | Press Release: Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update |
05.06 07:00 | Press Release: Addex Convenes Annual General Meeting 2024 |
31.05 07:00 | Press Release: Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024 |
08.05 07:00 | *DJ Addex to Present at BioEURquity Europe 2024 |
08.05 07:00 | Press Release: Addex to Present at BioEURquity Europe 2024 |
29.04 07:00 | *DJ Addex Provides Update on ADX71149 Phase 2 Epilepsy Study |
29.04 07:00 | Press Release: Addex Provides Update on ADX71149 Phase 2 Epilepsy Study |
19.04 07:00 | *DJ Addex to Present at the Swiss Biotech Day 2024 |
19.04 07:00 | Press Release: Addex to Present at the Swiss Biotech Day 2024 |
18.04 07:00 | *DJ Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update |
18.04 07:00 | Press Release: Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update |
11.04 07:00 | Press Release: Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024 |
03.04 07:00 | *DJ Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders |
03.04 07:00 | Press Release: Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders |
03.04 07:00 | Press Release: Addex and Perceptive Launch -2- |
14.03 07:00 | *DJ Addex to Present at the Bio-Europe Spring 2024 Conference |
14.03 07:00 | Press Release: Addex to Present at the Bio-Europe Spring 2024 Conference |
31.01 07:00 | *DJ Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC. |
31.01 07:00 | Press Release: Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC. |
|